Financings in Brief: Meridian Diagnostics
This article was originally published in The Gray Sheet
Executive SummaryMeridian Diagnostics: Immunodiagnostic kit manufacturer files registration statement with SEC for an offering of convertible subordinated debentures worth a principal amount of $12.5 mil. Net proceeds from the offering will be used for "possible acquisitions and licensing of products or technologies and general corporate purposes," Meridian says. Underwriters Roney & Co. will receive an over-allotment option to buy $1.9 mil. in convertible debentures...
You may also be interested in...
Civica Rx has won an investment of $55m through a deal with the Blue Cross Blue Shield Association of US health insurance firms to create a new subsidiary that will acquire and develop generic filings to be launched in the US from 2022.
Pfizer has launched its Ruxience rituximab biosimilar in the US at a 24% discount to the wholesale acquisition cost of the Rituxan original. The firm has also revealed that when it launches its Trazimera trastuzumab biosimilar in mid-February, it will be at a 22% discount to the Herceptin brand’s WAC.
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.